ATE393764T1 - Polymorphe formen von valsartan - Google Patents
Polymorphe formen von valsartanInfo
- Publication number
- ATE393764T1 ATE393764T1 AT04757623T AT04757623T ATE393764T1 AT E393764 T1 ATE393764 T1 AT E393764T1 AT 04757623 T AT04757623 T AT 04757623T AT 04757623 T AT04757623 T AT 04757623T AT E393764 T1 ATE393764 T1 AT E393764T1
- Authority
- AT
- Austria
- Prior art keywords
- valsartan
- polymorphous forms
- polymorphous
- forms
- crystalline
- Prior art date
Links
- 239000004072 C09CA03 - Valsartan Substances 0.000 title abstract 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title abstract 2
- 229960004699 valsartan Drugs 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45528603P | 2003-03-17 | 2003-03-17 | |
| US47364003P | 2003-05-28 | 2003-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE393764T1 true ATE393764T1 (de) | 2008-05-15 |
Family
ID=33032685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04757623T ATE393764T1 (de) | 2003-03-17 | 2004-03-17 | Polymorphe formen von valsartan |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20040242661A1 (de) |
| EP (1) | EP1511739B1 (de) |
| AT (1) | ATE393764T1 (de) |
| CA (1) | CA2519490A1 (de) |
| DE (1) | DE602004013405T2 (de) |
| ES (1) | ES2238022T3 (de) |
| WO (1) | WO2004083192A1 (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7199144B2 (en) | 2003-04-21 | 2007-04-03 | Teva Pharmaceuticals Industries, Ltd. | Process for the preparation of valsartan and intermediates thereof |
| EP1556363A2 (de) * | 2003-04-21 | 2005-07-27 | Teva Pharmaceutical Industries Limited | Verfahren zur herstellung von valsartan und zwischenprodukte davon |
| TW200505879A (en) * | 2003-04-21 | 2005-02-16 | Teva Pharma | Process for the preparation of valsartan |
| WO2005049588A1 (en) * | 2003-11-21 | 2005-06-02 | Ranbaxy Laboratories Limited | Process for isolation of valsartan |
| WO2005049587A1 (en) * | 2003-11-21 | 2005-06-02 | Ranbaxy Laboratories Limited | Process for preparation of biphenyl tetrazole |
| EP1661891A1 (de) * | 2004-11-30 | 2006-05-31 | KRKA, D.D., Novo Mesto | Verfahren zur Herstellung von Valsartan |
| AU2005318365B2 (en) | 2004-12-24 | 2011-02-03 | Krka, D.D., Novo Mesto | Solid pharmaceutical composition comprising valsartan |
| WO2006076561A1 (en) * | 2005-01-11 | 2006-07-20 | Teva Pharmaceutical Industries Ltd. | Process for preparing amorphous valsartan |
| WO2007017897A2 (en) * | 2005-05-25 | 2007-02-15 | Ipca Laboratories Ltd. | Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)bi-phenyl-4-ylmethyl]-amine |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| US20070166372A1 (en) * | 2006-01-19 | 2007-07-19 | Mai De Ltd. | Preparation of solid coprecipitates of amorphous valsartan |
| CZ300801B6 (cs) * | 2006-06-07 | 2009-08-12 | Helvetia Pharma A.S. | Kompozice s valsartanem v pevných lékových formách |
| WO2008035364A2 (en) * | 2006-06-23 | 2008-03-27 | Usv Limited | Process for the preparation of micronized valsartan |
| US20080004313A1 (en) * | 2006-06-28 | 2008-01-03 | Mai De Ltd. | Preparation of crystalline polymorphs of rimonabant hydrochloride |
| EP2057144A4 (de) * | 2006-09-01 | 2010-06-02 | Hetero Drugs Ltd | Neue polymorphe aus rimonabant |
| PL2295035T3 (pl) | 2007-11-06 | 2016-11-30 | Podwójne działanie kompozycji farmaceutycznych opartych na superstrukturach antagonisty/blokera receptora angiotensyny (arb) oraz inhibitora obojętnej endopeptydazy (nep) | |
| RU2010139567A (ru) * | 2008-02-28 | 2012-04-10 | Новартис АГ (CH) | Содержащие валсартан твердые оральные лекарственные формы и способы их изготовления |
| EP2389162A1 (de) | 2009-01-26 | 2011-11-30 | Teva Pharmaceutical Industries Ltd | Verfahren zur beschichtung eines trägers mit mikroteilchen |
| BR112013002589A2 (pt) | 2010-08-03 | 2019-09-24 | Novartis Ag | valsatana altamente cristalina |
| KR102495018B1 (ko) | 2013-11-15 | 2023-02-06 | 아케비아 테라퓨틱스 인코포레이티드 | ｛[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노｝아세트산의 고체형, 이의 조성물 및 용도 |
| WO2016001844A1 (en) * | 2014-06-30 | 2016-01-07 | Sun Pharmaceutical Industries Limited | Amorphous form of afatinib dimaleate |
| JP6382736B2 (ja) * | 2015-02-02 | 2018-08-29 | 株式会社トクヤマ | バルサルタンの製造方法 |
| JP2016150917A (ja) * | 2015-02-17 | 2016-08-22 | 株式会社トクヤマ | バルサルタンの結晶の製造方法 |
| WO2017012600A1 (en) | 2015-07-20 | 2017-01-26 | Zentiva, K.S. | A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
| US20200276129A1 (en) | 2017-10-13 | 2020-09-03 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Tablet containing valsartan and sacubitril |
| US10703728B1 (en) * | 2019-06-18 | 2020-07-07 | Scinopharm Taiwan, Ltd. | Crystalline form of olaparib and a process for preparing the same |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE134624T1 (de) * | 1990-02-19 | 1996-03-15 | Ciba Geigy Ag | Acylverbindungen |
| US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
| US5260325A (en) * | 1991-08-19 | 1993-11-09 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking tertiary amides |
| EP0668272B1 (de) * | 1994-01-28 | 2000-07-12 | Takeda Chemical Industries, Ltd. | Ein Verfahren zur Herstellung von Tetrazolyl-Verbindungen |
| WO1997030036A1 (en) | 1996-02-15 | 1997-08-21 | Novartis Ag | Aryl derivatives |
| GB9613470D0 (en) * | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| IT1292437B1 (it) * | 1997-06-30 | 1999-02-08 | Zambon Spa | Processo di orto-metallazione utile per la sintesi di 1 - tetrazol- 5-il) benzeni 2-sostituiti |
| IT1301759B1 (it) | 1998-06-19 | 2000-07-07 | Nicox Sa | Sali nitrati di farmaci antiipertensivi |
| US6465502B1 (en) * | 1998-12-23 | 2002-10-15 | Novartis Ag | Additional therapeutic use |
| US6395728B2 (en) * | 1999-07-08 | 2002-05-28 | Novartis Ag | Method of treatment and pharmaceutical composition |
| AU2001267404A1 (en) | 2000-05-04 | 2001-11-12 | Ipf Pharmaceuticals Gmbh | Novel compounds for the treatment of inflammatory and cardiovascular diseases |
| DK1313714T3 (da) * | 2000-07-19 | 2008-12-15 | Novartis Ag | Valsartansalte |
| US6869970B2 (en) * | 2002-02-04 | 2005-03-22 | Novartis Ag | Crystalline salt forms of valsartan |
| UY27668A1 (es) | 2002-02-20 | 2003-10-31 | Pfizer Prod Inc | Composición de ziprasidona y controles sintéticos |
| AU2003223637A1 (en) * | 2002-04-15 | 2003-11-03 | Dr. Reddy's Laboratories Limited | Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan) |
| GB0222056D0 (en) * | 2002-09-23 | 2002-10-30 | Novartis Ag | Process for the manufacture of organic compounds |
| US7199144B2 (en) * | 2003-04-21 | 2007-04-03 | Teva Pharmaceuticals Industries, Ltd. | Process for the preparation of valsartan and intermediates thereof |
-
2004
- 2004-03-17 WO PCT/US2004/008322 patent/WO2004083192A1/en not_active Ceased
- 2004-03-17 CA CA002519490A patent/CA2519490A1/en not_active Abandoned
- 2004-03-17 ES ES04757623T patent/ES2238022T3/es not_active Expired - Lifetime
- 2004-03-17 EP EP04757623A patent/EP1511739B1/de not_active Expired - Lifetime
- 2004-03-17 US US10/802,627 patent/US20040242661A1/en not_active Abandoned
- 2004-03-17 DE DE602004013405T patent/DE602004013405T2/de not_active Expired - Fee Related
- 2004-03-17 AT AT04757623T patent/ATE393764T1/de not_active IP Right Cessation
-
2005
- 2005-05-27 US US11/140,148 patent/US7105557B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1511739B1 (de) | 2008-04-30 |
| US20050222233A1 (en) | 2005-10-06 |
| WO2004083192A1 (en) | 2004-09-30 |
| US7105557B2 (en) | 2006-09-12 |
| US20040242661A1 (en) | 2004-12-02 |
| EP1511739A1 (de) | 2005-03-09 |
| ES2238022T3 (es) | 2008-11-01 |
| DE602004013405T2 (de) | 2009-05-07 |
| CA2519490A1 (en) | 2004-09-30 |
| DE602004013405D1 (de) | 2008-06-12 |
| ES2238022T1 (es) | 2005-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE393764T1 (de) | Polymorphe formen von valsartan | |
| NZ592897A (en) | Crystals of laquinimod sodium, and process for the manufacture thereof | |
| HUP0400446A2 (hu) | Azitromicin kristályformái | |
| BRPI0414599A (pt) | pirrol-indóis substituìdos | |
| DE60325498D1 (de) | 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen | |
| CY1112653T1 (el) | Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης | |
| BRPI0414598A (pt) | indóis substituìdos | |
| EP1873254A4 (de) | Verzweigte stärke, verfahren zur herstellung davon und verwendung davon | |
| NO20071254L (no) | Fremgangsmate for fremstilling av irbesartan og mellomprodukter derav. | |
| DK1546122T3 (da) | Fremgangsmåde til fremstilling af valsartan | |
| UA93531C2 (en) | Novel hydrogen sulfate salt | |
| DE602006017980D1 (de) | 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie | |
| NO20062021L (no) | Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika | |
| TW200615272A (en) | Crystalline mycophenolate sodium | |
| NO20070550L (no) | Fremgangsmate for fremstilling av pyrrolotriazinforbindelser | |
| NO20083269L (no) | Prosess for a anvende krystallinsk orlistatmetoder | |
| DE602005015963D1 (de) | Estergebundene makrolide, die sich für die behandlung von mikrobiellen infektionen eignen | |
| TW200510323A (en) | Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives | |
| ATE410166T1 (de) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate zur behandlung von unfruchtbarkeit | |
| CL2008002377A1 (es) | Procedimiento de preparacion de compuestos derivados de 3-piperidin-4-il-1,3,4,5-tetrahidro-benzo[d][1,3]diazepin-2-ona; compuestos intermediarios; y su procedimiento de preparacion. | |
| EP1565448A4 (de) | VERFAHREN ZUR HERSTELLUNG VON10H-DIBENZOçB, F] ç1,4]THIAZEPIN-11-ON | |
| FR2858334B1 (fr) | Solide cristallise im-11 de type structural lta et son procede de preparation | |
| EP1682627A4 (de) | Verfahren zur herstellung von methyllithium | |
| MY136854A (en) | Crystalline n-formyl hydroxylamine compounds | |
| NO20082379L (no) | Fremgangsmate for fremstilling av renset krystallinsk CCI-779 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |